Wells Fargo Maintains Overweight on Avidity Biosciences, Lowers Price Target to $50

Benzinga · 05/11/2023 06:44
Wells Fargo analyst Yanan Zhu maintains Avidity Biosciences (NASDAQ:RNA) with a Overweight and lowers the price target from $55 to $50.